Business Description
Fusion Antibodies PLC
ISIN : GB00BDQZGK16
Share Class Description:
LSE:FAB: Ordinary SharesTotal Employee Number:
18Description
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.65 | |||||
Equity-to-Asset | 0.4 | |||||
Debt-to-Equity | 0.53 | |||||
Debt-to-EBITDA | -0.27 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -2.15 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -52.4 | |||||
3-Year EBITDA Growth Rate | 8.2 | |||||
3-Year EPS without NRI Growth Rate | 26.9 | |||||
3-Year FCF Growth Rate | 15.3 | |||||
3-Year Book Growth Rate | -65.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 10.4 | |||||
9-Day RSI | 20.69 | |||||
14-Day RSI | 27.17 | |||||
3-1 Month Momentum % | -21.43 | |||||
6-1 Month Momentum % | -18.52 | |||||
12-1 Month Momentum % | 7.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.8 | |||||
Quick Ratio | 1.45 | |||||
Cash Ratio | 0.33 | |||||
Days Inventory | 75.41 | |||||
Days Sales Outstanding | 149.57 | |||||
Days Payable | 142.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -59.2 | |||||
Shareholder Yield % | -5.46 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 22.06 | |||||
Operating Margin % | -95.55 | |||||
Net Margin % | -91.92 | |||||
EBITDA Margin % | -88.66 | |||||
FCF Margin % | -77.63 | |||||
OCF Margin % | -73.87 | |||||
ROE % | -179.34 | |||||
ROA % | -94.38 | |||||
ROIC % | -208.08 | |||||
3-Year ROIIC % | 29.91 | |||||
ROC (Joel Greenblatt) % | -280.64 | |||||
ROCE % | -161.46 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 6.96 | |||||
PB Ratio | 16.25 | |||||
Price-to-Tangible-Book | 9.75 | |||||
EV-to-EBIT | -8.11 | |||||
EV-to-EBITDA | -8.72 | |||||
EV-to-Forward-EBITDA | -11.74 | |||||
EV-to-Revenue | 7.73 | |||||
EV-to-Forward-Revenue | 5.88 | |||||
EV-to-FCF | -10.97 | |||||
Price-to-GF-Value | 2.44 | |||||
| Price-to-Net-Current-Asset-Value | 9.75 | |||||
Earnings Yield (Greenblatt) % | -12.34 | |||||
FCF Yield % | -10.16 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fusion Antibodies PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | 1.596 | ||
| EPS (TTM) (£) | -0.015 | ||
| Beta | 0.0114 | ||
| 3-Year Sharpe Ratio | 0.37 | ||
| 3-Year Sortino Ratio | 0.7 | ||
| Volatility % | 62.64 | ||
| 14-Day RSI | 27.17 | ||
| 14-Day ATR (£) | 0.011889 | ||
| 20-Day SMA (£) | 0.10715 | ||
| 12-1 Month Momentum % | 7.32 | ||
| 52-Week Range (£) | 0.09 - 0.21 | ||
| Shares Outstanding (Mil) | 125.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fusion Antibodies PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fusion Antibodies PLC Stock Events
| Event | Date | Price (£) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2026-11-25 11:00 | In 117 days | ||
| Second quarter earnings results for 2027 | 2026-11-24 | In 115 days | ||
| General meeting for 2026 | 2026-10-16 10:00 | In 77 days | ||
| Annual report for 2026 | 2026-09-18 | In 48 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-09-15 10:00 | In 46 days | ||
| Fourth quarter earnings results for 2026 | 2026-09-04 | In 34 days | ||
| Second quarter earnings conference call for 2026 | 2025-11-25 11:00 | 0.12 (-2.08%) | ||
| Second quarter earnings results for 2026 | 2025-11-24 | 0.12 (-4.00%) | ||
| General meeting for 2025 | 2025-10-16 10:00 | 0.13 (-1.85%) | ||
| Annual report for 2025 | 2025-09-19 | 0.16 (-7.14%) |
Show
Entries
Fusion Antibodies PLC Frequently Asked Questions
What is Fusion Antibodies PLC(LSE:FAB)'s stock price today?
The current price of LSE:FAB is £0.10. The 52 week high of LSE:FAB is £0.21 and 52 week low is £0.09.
When is next earnings date of Fusion Antibodies PLC(LSE:FAB)?
The next earnings date of Fusion Antibodies PLC(LSE:FAB) is 2026-09-04 Est..
Does Fusion Antibodies PLC(LSE:FAB) pay dividends? If so, how much?
Fusion Antibodies PLC(LSE:FAB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Fusion Antibodies PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers